Literature DB >> 34969254

Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials.

Imogen Hawley1, Mei Song2, Rachel Scheckter3, Tara McClure3, Jeanna Piper4, Beatrice A Chen5, Craig Hoesley6, Albert Y Liu7,8, Ariane van der Straten8,9.   

Abstract

Vaginal rings address a critical need for an independently initiated, long-acting HIV prevention method, but their design must be acceptable to promote uptake and adherence. Human-centered design (HCD) may help address design preference questions. In two Phase I studies of vaginal rings for HIV prevention conducted in the United States, we used qualitative interviews to assess participants' perceptions and opinions of the physical characteristics of the ring they used and of a ring's physical characteristics after comparing four ring designs presented via a visual tool. Users were found to prefer ring designs that appear easy to use, are physically comfortable, that function well, and are aesthetically pleasing. The parameters for these features varied widely. Product developers and marketers should consider marketing messages in which the target users feel this product is made to meet their needs and desires. Product developers are encouraged to design using HCD early in ring development (Clinical Trial Registration number: NCT03234400 and NCT03670355).

Entities:  

Keywords:  HIV prevention; human-centered design; qualitative research; vaginal rings; visual tools

Mesh:

Year:  2022        PMID: 34969254      PMCID: PMC9048173          DOI: 10.1089/AID.2021.0077

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   1.723


  33 in total

1.  Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.

Authors:  Rochelle K Rosen; Jacob J van den Berg; Sara E Vargas; Natali Senocak; Julia G Shaw; Robert W Buckheit; Kelley Alison Smith; Kate Morrow Guthrie
Journal:  Contraception       Date:  2015-08-11       Impact factor: 3.375

2.  Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties.

Authors:  Kathleen M Morrow; Joseph L Fava; Rochelle K Rosen; Sara Vargas; Candelaria Barroso; Anna L Christensen; Cynthia Woodsong; Lawrence Severy
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

3.  User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.

Authors:  Kathleen M Morrow; Kristen Underhill; Jacob J van den Berg; Sara Vargas; Rochelle K Rosen; David F Katz
Journal:  Arch Sex Behav       Date:  2014-01-23

4.  Facilitating Interviews in Qualitative Research With Visual Tools: A Typology.

Authors:  Stephanie M N Glegg
Journal:  Qual Health Res       Date:  2018-07-10

5.  A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027.

Authors:  José A Bauermeister; Jesse M Golinkoff; Alex Carballo-Diéguez; Rebecca Giguere; Daniela López; Craig J Hoesley; Beatrice A Chen; Peter Anderson; Charlene S Dezzutti; Julie Strizki; Carol Sprinkle; Faye Heard; Wayne Hall; Cindy Jacobson; Jennifer Berthiaume; Ashley Mayo; Barbra A Richardson; Jeanna Piper
Journal:  AIDS Behav       Date:  2020-02

6.  Disclosure of pharmacokinetic drug results to understand nonadherence.

Authors:  Ariane van der Straten; Elizabeth T Montgomery; Petina Musara; Juliane Etima; Sarita Naidoo; Nicole Laborde; Miriam Hartmann; Lisa Levy; Thola Bennie; Helen Cheng; Jeanna Piper; Cynthia I Grossman; Jeanne Marrazzo; Barbara Mensch
Journal:  AIDS       Date:  2015-10-23       Impact factor: 4.177

7.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

8.  Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.

Authors:  Marie C D Stoner; Erica N Browne; Holly M Gundacker; Imogen Hawley; Beatrice A Chen; Craig Hoesley; Rachel Scheckter; Jeanna Piper; Devika Singh; Mei Song; Albert Liu; Ariane van der Straten
Journal:  PLoS One       Date:  2022-02-22       Impact factor: 3.752

9.  Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial.

Authors:  Sarah T Roberts; Imogen Hawley; Ellen Luecke; Barbara Mensch; Theresa Wagner; Craig Hoesley; Tara McClure; Clara P Dominguez Islas; Jeanna M Piper; Albert Y Liu; Ariane van der Straten
Journal:  J Womens Health (Larchmt)       Date:  2021-10-19       Impact factor: 3.017

10.  Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States.

Authors:  Albert Y Liu; Clara Dominguez Islas; Holly Gundacker; Blazej Neradilek; Craig Hoesley; Ariane van der Straten; Craig W Hendrix; May Beamer; Cindy E Jacobson; Tara McClure; Tanya Harrell; Katherine Bunge; Brid Devlin; Jeremy Nuttall; Patrick Spence; John Steytler; Jeanna M Piper; Mark A Marzinke
Journal:  J Int AIDS Soc       Date:  2021-06       Impact factor: 6.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.